Please Wait

Applying Filters...

Technical details about Dabigatran, learn more about the structure, uses, toxicity, action, side effects and more

Dabigatran

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

95 Suppliers, 36 USDMF, 20 EU WC, 19 KDMF, 22 NDC API, 75 Listed Suppliers

DEVELOPMENTS

3 Drug(s) in Development

3 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

97 Suppliers

97 Suppliers

DOSSIERs // Finished Dosage Forms

126 Dossiers, 34 FDA Orange Book, 29 Europe, 6 Canada, 21 Australia, 5 South Africa, 31 Listed Dossiers

DRUG PRODUCT COMPOSITION

CAPSULE;ORAL - EQ 110MG BASE, CAPSULE;ORAL - EQ 150MG BASE, CAPSULE;ORAL - EQ 75MG BASE

RELATED EXCIPIENT COMPANIES

Suppliers, 12 Kerry, 10 Corel Pharma Chem, 7 Seppic, 6 Lonza Capsugel, 4 Ideal Cures Pvt Ltd, 3 Gangwal Chemicals, 3 Kima Chemical, 3 Roquette, 2 The Dow Chemical Company, 2 Microlex e.U, 2 Rochem International Inc, 2 Finar, 2 SPI Pharma, 1 DKSH, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 ACG Worldwide, 1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Sigachi Industries, 1 Aeon Procare, 1 BASF, 1 Nanjing Well Pharmaceutical, 1 Gangwal Healthcare

EXCIPIENTS BY APPLICATIONS

41 Coating Systems & Additives, 19 Controlled & Modified Release, 9 Film Formers & Plasticizers, 7 Fillers, Diluents & Binders, 5 Empty Capsules, 4 Vegetarian Capsules, 4 API Stability Enhancers, 3 Parenteral, 3 Solubilizers, 3 Direct Compression, 3 Emulsifying Agents, 3 Thickeners and Stabilizers, 2 Lubricants & Glidants, 2 Disintegrants & Superdisintegrants, 2 Granulation, 2 Taste Masking, 2 Coloring Agents, 2 Topical, 1 Chewable & Orodispersible Aids, 1 Co-Processed Excipients, 1 Soft Gelatin, 1 Rheology Modifiers

GLOBAL SALES INFORMATION

8 US Medicaid Prescriptions, 28 Finished Drug Prices

MARKET PLACE

13 APIs, 4 DOSSIERS // FDF

PATENTS

26 US Patents, 18 US Exclusivities

ANALYTICAL SOLUTION(s)

1 Other Ref. Standards

1 Other Ref. Standards

DIGITAL CONTENT

4 Data Compilation & Company Tracker #PharmaFlow, 74 News

1. Also known as: Dabigatran etexilate mesylate, 872728-81-9, Pradaxa, Ethyl 3-[[2-[[4-[(z)-n'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic acid, Dtxsid20236248, Ex-a1966

Molecular Formula

C₃₅H₄₅N₇O₈S

Molecular Weight

723.8 g/mol

InChI Key

XETBXHPXHHOLOE-UHFFFAOYSA-N

A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

1 2D Structure

2D Structure

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

ethyl 3-[[2-[[4-[(Z)-N'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic acid

2.1.2 InChI

InChI=1S/C34H41N7O5.CH4O3S/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29;1-5(2,3)4/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44);1H3,(H,2,3,4)

2.1.3 InChI Key

XETBXHPXHHOLOE-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CCCCCCOC(=O)N=C(C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)N.CS(=O)(=O)O

2.1.5 Isomeric SMILES

CCCCCCOC(=O)/N=C(/C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)\N.CS(=O)(=O)O

2.2 Synonyms

2.2.1 MeSH Synonyms

1. Bibr 1048

2. Dabigatran

3. Dabigatran Etexilate

4. Dabigatran Etexilate Mesylate

5. Etexilate Mesylate, Dabigatran

6. Etexilate, Dabigatran

7. Mesylate, Dabigatran Etexilate

8. N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)-n-2-pyridinyl-beta-alanine

9. Pradaxa

2.2.2 Depositor-Supplied Synonyms

1. Dabigatran Etexilate Mesylate

2. 872728-81-9

3. Pradaxa

4. Ethyl 3-[[2-[[4-[(z)-n'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic Acid

5. Dtxsid20236248

6. Ex-a1966

7. Mfcd25424070

8. S5960

9. Ccg-213236

10. Cs-w004358

11. (z)-ethyl 3-(2-(((4-(n'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-n-(pyridin-2-yl)-1h-benzo[d]imidazole-5-carboxamido)propanoate Methanesulfonate

12. 728p819

2.3 Create Date

2006-10-26

3 Chemical and Physical Properties

Molecular Formula	C₃₅H₄₅N₇O₈S
Molecular Weight	723.8 g/mol
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	17
Exact Mass	723.30503259 g/mol
Monoisotopic Mass	723.30503259 g/mol
Topological Polar Surface Area	217 Å²
Heavy Atom Count	51
Formal Charge	0
Complexity	1100
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Pradaxa
PubMed Health	Dabigatran (By mouth)
Drug Classes	Anticoagulant
Drug Label	The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfo...
Active Ingredient	Dabigatran etexilate mesylate
Dosage Form	Capsule
Route	Oral
Strength	eq 150mg base; eq 75mg base
Market Status	Prescription
Company	Boehringer Ingelheim

2 of 2
Drug Name	Pradaxa
PubMed Health	Dabigatran (By mouth)
Drug Classes	Anticoagulant
Drug Label	The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfo...
Active Ingredient	Dabigatran etexilate mesylate
Dosage Form	Capsule
Route	Oral
Strength	eq 150mg base; eq 75mg base
Market Status	Prescription
Company	Boehringer Ingelheim

4.2 Drug Indication

Pradaxa 75 mg

- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

Pradaxa 110 mg

- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 75 years; heart failure (NYHA Class II); diabetes mellitus; hypertension.

- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

Pradaxa 150 mg

- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Antithrombins

Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. (See all compounds classified as Antithrombins.)

5.2 FDA Pharmacological Classification

5.2.1 Pharmacological Classes

Thrombin Inhibitors [MoA]; Direct Thrombin Inhibitor [EPC]

5.3 ATC Code

B01AE07

POST ENQUIRY